High materiality7/10
Canaccord Reiterates Buy Rating on Pharming Group (PHAR)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
PHAR received a Buy rating reaffirmation from Canaccord Genuity; target $38 vs current price $11.26, implying meaningful upside.
- Canaccord reiterates Buy on PHAR; target $38.
- Current price $11.26.
Key facts
- 01
Target: $38
- 02
Posted price: $11.26
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Whitney Ijem
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.